This information is for research and educational purposes only. No medical recommendations. Products are not approved for human use. For health questions, consult a doctor.

Lexicon

CJC-1295 without DAC

The short-acting GHRH analog (Mod GRF 1-29) that triggers a clean GH pulse, ideal as a partner to a GHRP.

3 min read 7 sources

CJC-1295 without DAC vial with white powder and the black TPD label on a white podium, next to a large blue 3D peptide model in a bright lab
No study of its own · not approved

Summary

At a glance

Sources checked on 26 Oct 2026

Length
29 amino acids

the first 29 building blocks of GHRH, the active chain2

Substituted
4 building blocks

four-fold modified GRF(1-29), without the albumin anchor of the DAC version2

For comparison: with DAC
8.1 days

half-life of the DAC version up to 8.1 days, without the anchor the peptide acts only briefly3

Own human trials
0 trials

no trial with the version without DAC on ClinicalTrials.gov, as of 26 Oct 20266

  • CJC-1295 without DAC, also called Mod GRF 1-29, is the first 29 building blocks of the body's own GHRH with four substituted building blocks. It lacks the chemical anchor with which the DAC version binds to albumin.2
  • It acts on the GHRH receptor of the pituitary and is meant to trigger a short pulse of growth hormone there. Without the anchor it acts only briefly, while the DAC version lasts for days.23
  • There is no published study of its own on the version without DAC. The studies in healthy adults under the name CJC-1295 all tested the DAC version.631
  • That a GHRH signal and a ghrelin mimetic together release more growth hormone than either alone was shown in a study in healthy men with GHRH and GHRP-6.5
  • In 2010 a doping lab found a 29-building-block peptide without an anchor sold under the name CJC-1295. Not approved, everything here is the state of research, not a recommendation.46
Profile

Updated May 2026

How long does it stay in the body?

Share left after one dose, calculated with a half-life of ~30 minutes

Half-life ~30 minutes
After 60 minutes: 25 %
Minute 30 · 50 %Minute 60 · 25 %Minute 90 · 12.5 %Minute 150 · 3.1 %

Simplified model without an absorption phase, half-life from the TPD lexicon.

Class
GHRH analog

short-acting

Use
Subcutaneous

in mcg

Half-life
short

approx. 30 minutes

WADA
Banned

peptide hormones

Sizes
2 to 10 mg

3 sizes in the shop

Contents 16 sections
  1. At a glance
  2. What is CJC-1295 without DAC?
  3. How it works
  4. What you need
  5. Reconstitution
  6. Dosing
  7. Injection
  8. What the research shows
  9. Research status
  10. Side effects
  11. Practice
  12. Storage
  13. Related compounds
  14. FAQ
  15. Glossary
  16. Sources

What is CJC-1295 without DAC?

CJC-1295 without DAC, also called Mod GRF 1-29, is a short-acting analog of the body's own GHRH (the hormone that triggers growth hormone release). Unlike the DAC variant it does not bind albumin long term but acts only briefly, with a clean, pulsatile GH rise.

That makes it the classic partner for a GHRP like Ipamorelin: the GHRH analog provides one signal, the GHRP the other, together a stronger pulse than either alone.

Comparison

GHRH, ghrelin or the hormone itself

Where each compound acts, as stated in the TPD lexicon. Tap a card to open its entry.

How it works

CJC-1295 without DAC docks at the GHRH receptor of the pituitary and triggers a short GH pulse there, similar to the natural rhythm. Because the effect fades quickly, the body's own pulse pattern stays intact.

Combined with a ghrelin mimetic (GHRP), two different signaling routes interlock and GH output is markedly higher than with either alone.

Where it acts

Where CJC-1295 without DAC acts

Tap a point or a card. Colour = GHRH receptor. Derived from the backbone, without a study of its own.

  1. Pituitary

    GHRH receptor, through which growth hormone release starts2

    GHRH

Known targets2

One described target, Target of the GRF(1-29) backbone, like the body's own GHRH.

GHRH receptor
Gene
GHRHR
UniProt
Q02643
ChEMBL
CHEMBL2032
Action
Target of the GRF(1-29) backbone, like the body's own GHRH
Two different glass receptor shapes on a light blue cell surface, a blue 3D peptide chain docks onto the left one with a short flash of light, a second chain onto the right one
Symbolic image.

What you need

Supplies

4 things, numbered as in the picture

Tick off what you already have. Vial and BAC water are our real shop photos at the same size.

CJC-1295 without DAC vial and bacteriostatic water at the same size with the black TPD label, next to two U-100 insulin syringes, two alcohol swabs and a sharps container with a blue lid
  1. CJC-1295 vial

    The CJC-1295 vial (lyophilized powder).

    In the shop
  2. Bacteriostatic water

    Bacteriostatic water for mixing.

    In the shop
  3. U-100 insulin syringes

    U-100 insulin syringes.

  4. Alcohol swabs

    Alcohol swabs and a clean workspace.

As an Amazon associate we earn from qualifying purchases. Links open Amazon - no extra cost for you.

Reconstitution

Use the peptide calculator: pick vial size and water amount, it shows concentration and units per shot on the U-100 syringe.

A 5mg vial with 2ml water gives 2500mcg per ml, a 100mcg shot is then 4 units on the syringe. Just add the water to the vial and let it dissolve.

Step by step

Dissolving the powder

Four steps, the same for every vial size.

  1. 1Wipe the cap

    Clean the rubber stopper with an alcohol swab.

  2. 2Add BAC water

    Just add it, it does not matter if it hits the powder directly.

  3. 3Swirl or shake

    Until everything has dissolved, both are fine.

  4. 4Draw up

    With the U-100 insulin syringe.

Less water higher concentration fewer units on the syringe Example: 5 mg + 2 ml = 2.5 mg/ml

Dosing

Dosing

Dosing, titration and syringe

Loading the dosing information …

  • Getting started and stepping up, drawn as a staircase
  • Units on the U-100 syringe for every step
  • How long one vial lasts

Injection

The injection is subcutaneous, into the fat layer under the skin. Common spots are the abdomen (keep about two finger-widths clear of the navel), the front and the inner side of the thigh, or the back of the upper arm.

The short version:

Injection

Where and at what angle

Pick a spot or switch the angle. Subcutaneous means: into the fat layer, not the muscle.

Rotate the spot each time, never the same one twice in a row.

90°More fat under the skin

Rule of thumb: where there is more fat under the skin, insert straight at 90 degrees. In lean people with little fat, 45 degrees, so the needle stays in the fat layer. Simplified diagram.

  1. Clean the spot with an alcohol swab and let it dry

  2. Pinch up a small fold of skin

  3. Insert the needle: at 90 degrees where there is more fat under the skin, at 45 degrees in lean people with little fat

  4. Inject slowly, wait a moment, then withdraw

  5. Put the needle straight into the sharps container

Rotate the site each time so the tissue does not get irritated. Never the same spot twice in a row.

Use the short insulin needle, ideally fasted with some gap to meals, because carbs and fat dampen the GH pulse.

What the research shows

The pharmacology of the CJC-1295 family was studied in healthy adults (Ionescu & Frohman, 2006): GHRH analogs raise GH and IGF-1 while the natural pulse pattern stays intact. The DAC variant acts for days, the form without DAC described here only briefly.

For the short-acting variant, most comes from GHRH-analog research and the practice of pairing it with GHRPs, no standalone approval exists.

Glass sculpture of two drop shapes with wavy trails of light on a bright lab bench, racks of sample tubes on the left and right
Symbolic image.

Research status

Where the research stands

No trial is registered for the version without DAC. The only registered CJC-1295 trial (phase 2, terminated early in 2006) used the DAC version and is listed in that entry. As of 26 Oct 2026. 6

  1. Preclinical Modified GRF(1-29) as the backbone, tested in rats only with the anchor
  2. Phase 1 no registered trial
  3. Phase 2 no registered trial
  4. Phase 3 no registered trial
  5. Approval not yet
Not approved and no registered human trial. According to the entry banned in official competition.6

So far there is no registered trial in humans. 6

Side effects

  • Water retention, tingling, swollen hands, especially at higher GH levels.
  • Redness or itching at the injection site.
  • Tiredness or grogginess shortly after the injection (typical of the GH pulse).

Practice

  1. Useful as a GHRH partner to a GHRP, on its own the effect is weaker.

  2. Fasted and before sleep makes best use of the natural GH window.

  3. Banned in official competition.

Bed with a light blue sleep mask on the pillow, a glass of water and an empty plate on the bedside table, outside the full moon over the sea

Storage

Before mixing the powder is robust, normal room temperature (around 20 to 25 degrees) is fine, ideally kept in the dark. After mixing, keep in the fridge (2 to 8 degrees), do not freeze. It stays good there for at least 4 to 6 months with barely any loss of potency, in practice considerably longer. Swirl or shake to mix, both are fine.

Shelf life

How long it keeps

Undissolved (powder) Room temperature, around 20 to 25 degrees, dark

Robust, no fridge needed. Keeps for several months without trouble.

Dissolved (mixed) Fridge, 2 to 8 degrees, do not freeze

At least 4 to 6 months with barely any loss of potency. The bacteriostatic water brings a preservative.

  • Keep it dark
  • Dissolved: 2 to 8 degrees
  • Note the mixing date on the vial
Nine vials with white powder and blue caps in the door shelf of a bright fridge
Powder dark at room temperature, once dissolved into the fridge (2 to 8 degrees), stable there for at least 4 to 6 months. Symbolic image.

Related

Related compounds

Same receptors, blends with CJC-1295 without DAC or a different path: all in the TPD lexicon.

FAQ

Common questions about CJC-1295 without DAC

Short answers, each backed by the sources below.

Is CJC-1295 without DAC approved or studied in humans?

No. There is no approval and the registry ClinicalTrials.gov lists no trial with the version without DAC (as of 26 October 2026). PubMed has no human study of its own on it either.6

How does it differ from CJC-1295 with DAC?

Both share the same 29 modified GHRH building blocks. The DAC version additionally carries a chemical anchor that binds to albumin in the blood. In healthy adults its half-life was 5.8 to 8.1 days. Without the anchor this binding is missing and the peptide acts only briefly.23

Which study is behind the entry?

The entry cites a 2006 study in healthy men. There the pulsatile pattern of growth hormone was preserved. However, it tested the DAC version, one week after a dose. The figures cannot be transferred to the short version without DAC.1

Why is it combined with a GHRP?

A GHRH analogue and a GHRP act on the same release through two different receptors. In a study in 18 healthy men GHRH and the ghrelin mimetic GHRP-6 together released more growth hormone than the sum of each alone. This was not tested with CJC-1295 without DAC itself.5

What did a doping lab find?

In 2009 the Norwegian doping lab examined an unknown preparation for police and customs. It contained a 29-building-block peptide with the sequence sold under the name CJC-1295, so without the anchor. As a growth hormone releasing factor it is on the WADA prohibited list.4

Which side effects are known?

There are no solid data because the version without DAC has never been tested in a human study. The entry lists the typical consequences of more growth hormone such as water retention, tingling and injection-site reactions.6

Glossary

Terms explained briefly

Dotted words in the text open these explanations directly.

Albumin
The most common protein in blood plasma. It carries many substances and is itself broken down only slowly.
DAC
Drug Affinity Complex: a chemical anchor that attaches to albumin in the blood and keeps a peptide there for days. Missing in this version.
GHRH
Growth hormone-releasing hormone: a hormone from the hypothalamus that prompts the pituitary to release growth hormone. An analogue is a synthetically modified version of it.
GHRP
Growth hormone-releasing peptide: short peptides such as ipamorelin or GHRP-6 that trigger growth hormone release via the ghrelin receptor.
Growth hormone (GH)
Pituitary hormone. It is released in pulses (mostly in deep sleep) and promotes fat breakdown and tissue build-up.
Half-life
Time after which only half of a substance is left in the blood.
IGF-1
Insulin-like growth factor 1: messenger made mainly by the liver under growth hormone. Many effects of GH run through it.
Lyophilisate
Freeze-dried powder. Without water a peptide keeps much longer.
Mod GRF 1-29
Modified GRF (1-29): the first 29 building blocks of GHRH, substituted at four positions. Another name for CJC-1295 without DAC.
Pituitary
Small gland below the brain (hypophysis). It controls many hormones, including growth hormone.
Subcutaneous
Into the fat layer just under the skin.
WADA
World Anti-Doping Agency. Its prohibited list includes growth hormone releasing factors among the peptide hormones.

Evidence

Sources

Show all 7 sourcesHide sources 5 Studies1 Trial registry1 Database checked 26 Oct 2026

Studies

  1. GH pulses under CJC-1295 (the DAC version was tested)

    Ionescu und Frohman, Journal of Clinical Endocrinology & Metabolism, 2006

    Checked 26 Oct 2026 via doi.org, Crossref, PubMed
  2. Development of CJC-1295 from four-fold modified GRF(1-29) (rats)

    Jetté et al., Endocrinology, 2005

    Checked 26 Oct 2026 via doi.org, Crossref, PubMed
  3. Half-life of the DAC version in healthy adults (comparison)

    Teichman et al., Journal of Clinical Endocrinology & Metabolism, 2006

    Checked 26 Oct 2026 via doi.org, Crossref, PubMed
  4. Doping lab finds a peptide without anchor sold as CJC-1295

    Henninge et al., Drug Testing and Analysis, 2010

    Checked 26 Oct 2026 via doi.org, Crossref, PubMed
  5. GHRH and GHRP-6 amplify each other (healthy men)

    Bowers et al., Journal of Clinical Endocrinology & Metabolism, 1990

    Checked 26 Oct 2026 via doi.org, Crossref, PubMed

Trial registry

  1. Search on ClinicalTrials.gov (no trial without DAC)

    ClinicalTrials.gov, U.S. National Library of Medicine

    Checked 26 Oct 2026 via ClinicalTrials.gov API v2

Database

  1. GHRH receptor in ChEMBL

    ChEMBL, EMBL-EBI (CHEMBL2032, UniProt Q02643)

    Checked 26 Oct 2026 via ChEMBL, UniProt

In the shop

CJC-1295 without DAC in the catalog

Sizes, prices and shipping times are on the product page.

To the product